Acute stroke management

Stroke disease is the second leading cause of death in the world. Even if stroke incidence remains stable, the number of new acute strokes in Europe is projected to increase markedly by 2025. In 2007, the SITS-MOST trial provided the first conclusive evidence that intravenous thrombolysis with recombinant tissue plasminogen activator (rTPA) was beneficial in the acute period for patients with cerebral infarct. Evidence from the same year showed...